"In this particular case, the only thing I'd be impartial about is what prison he goes to," said a potential juror on day three of Martin Shkreli's high-profile court case, highlighting the challenge of jury selection.
FDA has announced two more initiatives designed to foster greater generics competition, a key priority for new commissioner Scott Gottlieb.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Marathon Pharmaceuticals is doing some backtracking after the public, the media and now Bernie Sanders objected to the list price of its upcycled corticosteroid for Duchenne muscular dystrophy.
Healthcare just won't stop colliding with pop culture, will it? In the wake of news about a Martin Shkreli musical, we also learn that athenahealth boss Jonathan Bush has responded to John Oliver.
Step aside, "Martin Shkreli's Game." Here are a few more inspired ideas from the healthcare and life sciences industry that could make it to the Great White Way.
Also, one group wants to tap videogamers' expertise to develop a better tuberculosis test and MVM Life Science Partners has closed its fourth fund at $233 million.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Valeant Pharmaceuticals just poached Perrigo CEO Joseph Papa to be its new chief executive. He'll replace the somewhat reviled current CEO, Michael Pearson, in early May.
The organization's all about generic drugs - but unlike, say, Martin Shkreli, Bloom's big idea is to repurpose existing drugs and lessen the overall costs of healthcare.
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
Also, a potentially game changing approach to kidney transplants and Alphabet is selling is robotics business.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The company is in trials for its drug, Firdapse, that treats LEMS. However, a generic form of that drug's been in use for decades.
Also, in the Democratic debate U.S. Sen Bernie Sanders goes after Hillary Clinton over pharma campaign donations influencing her position on drug prices, and a hospital CEO is arrested for prescription drug fraud.
During today’s congressional hearing on drug pricing, Rep. Jason Chaffetz (R-Utah) made his own case against the price gouging antics seen at Turing Pharmaceuticals. He pointed out a number of salary hikes seen last year among Turing’s top executives, as noted in documentation received by the House Oversight and Government Reform Committee in advance of the hearing. […]
Did he seem uncomfortable, or was the notorious pharma dudebro trying to project the confidence that so often has veered into arrogance since he became the poster child for runaway price hikes last year?
Congressmen were up in arms over Martin Shkreli's disrespectful behavior - and that fueled their attacks against drug pricing in the pharmaceutical industry. Here are four of their most interesting rants.